Emma J de Ruiter1, Reinout H de Roest2, Ruud H Brakenhoff2, C René Leemans2, Remco de Bree3, Chris H J Terhaard4, Stefan M Willems5. 1. Department of Pathology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands. e.j.deruiter-2@umcutrecht.nl. 2. Department of Otolaryngology/Head and Neck Surgery, Cancer Center Amsterdam, Amsterdam University Medical Center, Amsterdam, The Netherlands. 3. Department of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands. 4. Department of Radiotherapy, University Medical Center Utrecht, Utrecht, The Netherlands. 5. Department of Pathology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
Abstract
AIM: This study aimed to evaluate the presence and prognostic value of tumor-infiltrating T cells in the tumor epithelium in advanced stage, HPV-negative head and neck squamous cell carcinoma (HNSCC) patients treated with primary chemoradiotherapy using digital pathology. METHODS: Pre-treatment biopsies from 80 oropharyngeal, 52 hypopharyngeal, and 29 laryngeal cancer patients were collected in a tissue microarray (TMA) and immunohistochemically stained for T-cell markers CD3, CD4, CD8, FoxP3, and PD1, and for immune checkpoint PD-L1. For each marker, the number of positive tumor-infiltrating lymphocytes (TILs) per mm2 tumor epithelium was digitally quantified and correlated to overall survival (OS), disease-free survival (DFS), and locoregional control (LRC), as well as to clinicopathological characteristics. Differences in clinical outcome were estimated using Cox proportional hazard analysis and visualized using Kaplan-Meier curves. RESULTS: The patient cohort had a 3-year OS of 58%, with a median follow-up of 53 months. None of the T-cell markers showed a correlation with OS, DFS or LRC. A low N stage was correlated to a better prognosis (OS: HR 0.39, p = 0.0028, DFS: HR 0.34, p = < 0.001, LRC: HR 0.24, p = 0.008). High TIL counts were more often observed in PD-L1-positive tumors (p < 0.05). CONCLUSION: This study showed an objective, digital pathology-aided method to assess TILs in the tumor epithelium. However, it did not provide evidence for a prognostic role of the presence of CD3 + , CD4 + , CD8 + , FoxP3 + , and PD1 + TILs in the tumor epithelium of advanced stage, HPV-negative HNSCC patients treated with primary chemoradiotherapy.
AIM: This study aimed to evaluate the presence and prognostic value of tumor-infiltrating T cells in the tumor epithelium in advanced stage, HPV-negative head and neck squamous cell carcinoma (HNSCC) patients treated with primary chemoradiotherapy using digital pathology. METHODS: Pre-treatment biopsies from 80 oropharyngeal, 52 hypopharyngeal, and 29 laryngeal cancerpatients were collected in a tissue microarray (TMA) and immunohistochemically stained for T-cell markers CD3, CD4, CD8, FoxP3, and PD1, and for immune checkpoint PD-L1. For each marker, the number of positive tumor-infiltrating lymphocytes (TILs) per mm2tumor epithelium was digitally quantified and correlated to overall survival (OS), disease-free survival (DFS), and locoregional control (LRC), as well as to clinicopathological characteristics. Differences in clinical outcome were estimated using Cox proportional hazard analysis and visualized using Kaplan-Meier curves. RESULTS: The patient cohort had a 3-year OS of 58%, with a median follow-up of 53 months. None of the T-cell markers showed a correlation with OS, DFS or LRC. A low N stage was correlated to a better prognosis (OS: HR 0.39, p = 0.0028, DFS: HR 0.34, p = < 0.001, LRC: HR 0.24, p = 0.008). High TIL counts were more often observed in PD-L1-positive tumors (p < 0.05). CONCLUSION: This study showed an objective, digital pathology-aided method to assess TILs in the tumor epithelium. However, it did not provide evidence for a prognostic role of the presence of CD3 + , CD4 + , CD8 + , FoxP3 + , and PD1 + TILs in the tumor epithelium of advanced stage, HPV-negative HNSCCpatients treated with primary chemoradiotherapy.
Entities:
Keywords:
Head and neck squamous cell carcinoma (HNSCC); Prognostic biomarkers; T cells; Tumor-infiltrating lymphocytes (TILs)
Authors: Juan P Rodrigo; Mario Sánchez-Canteli; Fernando López; Gregory T Wolf; Juan C Hernández-Prera; Michelle D Williams; Stefan M Willems; Alessandro Franchi; Andrés Coca-Pelaz; Alfio Ferlito Journal: Biomedicines Date: 2021-04-28
Authors: Rachel A Woolaver; Xiaoguang Wang; Alexandra L Krinsky; Brittany C Waschke; Samantha M Y Chen; Vince Popolizio; Andrew G Nicklawsky; Dexiang Gao; Zhangguo Chen; Antonio Jimeno; Xiao-Jing Wang; Jing Hong Wang Journal: J Immunother Cancer Date: 2021-01 Impact factor: 13.751
Authors: Emma J de Ruiter; Sangeeta K Bisheshar; Reinout H de Roest; Frederik W R Wesseling; Frank J P Hoebers; Mari F C M van den Hout; C René Leemans; Ruud H Brakenhoff; Remco de Bree; Chris H J Terhaard; Stefan M Willems Journal: Virchows Arch Date: 2022-04-22 Impact factor: 4.535
Authors: Jun Jiang; Burak Tekin; Lin Yuan; Sebastian Armasu; Stacey J Winham; Ellen L Goode; Hongfang Liu; Yajue Huang; Ruifeng Guo; Chen Wang Journal: Front Med (Lausanne) Date: 2022-09-07
Authors: Shay Sharon; Thomas Duhen; Shelly Bambina; Jason Baird; Rom Leidner; Bryan Bell; Nardy Casap; Marka Crittenden; Swetha Vasudevan; Maria Jubran; Nataly Kravchenko-Balasha; Michael Gough Journal: Front Oncol Date: 2021-06-17 Impact factor: 6.244